Maximal Tumor Eradication for Oligometastatic Prostate Cancer

In China, the incidence of prostate cancer is increasing in recent years, and it has ranked 5th among common male tumors and 1st in urinary tumors. Unlike developed countries in Europe and the United States, in China, because prostate-specific antigen (PSA) screening has not been widely popularized, and early prostate cancer is mostly asymptomatic, about 13%-26% of prostate cancer patients have progressed to metastatic hormone-sensitive prostate cancer (mHSPC) at the time of initial diagnosis. Compared with localized prostate cancer, the 5-year survival rate of mHSPC is only 29.3%, which is pr

Trial Details

NCT ID
NCT06972511
Phase
PHASE2 / PHASE3
Sponsor
RenJi Hospital
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastases
  • Standard ADT treatment
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age less than 75 years
  • EORTC QLQC-30 score 2
  • Life expectancy of 10 years
  • Patients with oligometastatic prostate cancer on clinicopathological assessment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →